Iovance Biotherapeutics Inc Stock News

SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:

For a roller-coaster stock, look no further than Iovance Biotherapeutics (IOVA -1.22%).

Monday won't go down as a particularly memorable trading session on the stock market. It also won't be marked as a great day for shareholders of biotech Iovance Biotherapeutics (IOVA -5.95%).

There's at least one good thing to say about Iovance Biotherapeutics (IOVA 5.71%), a small-cap biotech. The drugmaker is an innovative company.

SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 21, 2025 (the “Date of Grant”), the Company approved the grant of induce...

IOVA's Amtagvi (lifileucel) launch shows progress with Q2'25 revenue growth, helping rebuild confidence after prior stagnation. Cash burn remains a concern, but the company announced a restructuring with Q2'25 earnings, to help it extend runway to Q4'26. Upcoming data from trials of lifileucel in lung and endometrial cancer could provide upside for the stock, as could a launch of Amtagvi in Can...

A piece of good news on the regulatory front and a subsequent bullish analyst update were the factors driving Iovance Biotherapeutics (IOVA 5.00%) stock higher on Tuesday. The shares were almost 6% in positive territory in the middle of today's trading session, contrasting very well with the 0.5% slide of the S&P 500 index.

First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy